5.8779

6.15% 0.3679

Emergent Biosolutions Inc (EBS)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$5.51

Offen:

$5.59

24-Stunden-Volumen:

207.05K

Relative Volume:

0.20

Marktkapitalisierung:

$321.85M

Einnahmen:

$1.02B

Nettoeinkommen (Verlust:

$-757.20M

KGV:

-0.3982

EPS:

-14.76

Netto-Cashflow:

$-257.90M

1W Leistung:

+1.36%

1M Leistung:

-39.83%

6M Leistung:

-25.68%

1J Leistung:

+148.88%

1-Tages-Spanne:

$5.59

$6.01

1-Wochen-Bereich:

$5.26

$6.36

52-Wochen-Spanne:

$1.8201

$15.10

Emergent Biosolutions Inc Stock (EBS) Company Profile

Firmenname

Emergent Biosolutions Inc

Sektor

Healthcare (1171)

Branche

Drug Manufacturers - Specialty & Generic (1)

Telefon

240-631-3200

Adresse

300 PROFESSIONAL DR, GAITHERSBURG, MD

Mitarbeiter

1,600

Twitter

@emergentbiosolu

Nächster Verdiensttermin

2025-03-03

Neueste SEC-Einreichungen

EBS's Discussions on Twitter

Vergleichen Sie EBS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EBS Emergent Biosolutions Inc	5.89	321.85M	1.02B	-757.20M	-257.90M	-14.76
ZTS Zoetis Inc	159.66	71.40B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.06	47.36B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.16	46.03B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.34	18.86B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.25	13.96B	612.78M	-86.37M	-62.91M	-0.87

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-08-22	Eingeleitet	Rodman & Renshaw	Buy
2024-03-07	Hochstufung	The Benchmark Company	Hold → Buy
2023-11-20	Fortgesetzt	JP Morgan	Underweight
2023-08-29	Herabstufung	The Benchmark Company	Buy → Hold
2023-04-10	Hochstufung	The Benchmark Company	Hold → Buy
2023-03-17	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-10	Herabstufung	The Benchmark Company	Buy → Hold
2022-04-29	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2022-01-20	Hochstufung	The Benchmark Company	Hold → Buy
2021-11-08	Herabstufung	The Benchmark Company	Buy → Hold
2021-05-05	Herabstufung	Argus	Buy → Hold
2021-04-07	Eingeleitet	The Benchmark Company	Buy
2021-02-24	Hochstufung	Chardan Capital Markets	Neutral → Buy
2021-02-19	Herabstufung	Chardan Capital Markets	Buy → Neutral
2021-01-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-07-31	Bestätigt	Chardan Capital Markets	Buy
2019-09-12	Eingeleitet	Guggenheim	Buy
2019-09-04	Hochstufung	Wells Fargo	Market Perform → Outperform
2018-11-02	Hochstufung	Goldman	Neutral → Buy
2018-08-03	Bestätigt	Chardan Capital Markets	Buy
2018-06-13	Eingeleitet	Argus	Buy
2018-04-25	Herabstufung	Wells Fargo	Outperform → Market Perform
2018-01-24	Eingeleitet	Goldman	Neutral
2018-01-16	Bestätigt	Chardan Capital Markets	Buy
2016-06-28	Bestätigt	Singular Research	Buy
2016-04-15	Eingeleitet	Chardan Capital Markets	Buy
2016-03-28	Eingeleitet	Singular Research	Buy
2016-02-19	Eingeleitet	Wells Fargo	Outperform
2014-05-15	Eingeleitet	Summer Street Research	Buy
2011-05-31	Bestätigt	WBB Securities	Strong Buy
2011-01-10	Bestätigt	Wedbush	Outperform
2010-11-05	Bestätigt	Wedbush	Outperform
2010-08-18	Hochstufung	WBB Securities	Buy → Strong Buy
2010-08-06	Bestätigt	Caris & Company	Buy

Alle ansehen

Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten

03:56 AM

Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN

03:56 AM

Mar 13, 2025

Emergent signs financial investment agreement with Swiss Rockets - Yahoo Finance

Mar 13, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times

Mar 13, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian

Mar 13, 2025

First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan

Mar 13, 2025

Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN

Mar 13, 2025

Mar 12, 2025

Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India

Mar 12, 2025

Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com

Mar 12, 2025

Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com UK

Mar 12, 2025

Emergent Bio and Rocketvax in investment deal and partnership - The Pharma Letter

Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement - Contract Pharma

Mar 12, 2025

Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates - Marketscreener.com

Mar 12, 2025

Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax -March 12, 2025 at 08:40 am EDT - Marketscreener.com

Mar 12, 2025

Emergent BioSolutions, Rocketvax announce investment agreement - TipRanks

Mar 12, 2025

Emergent BioSolutions and Rocketvax Ltd Announce Strategic Investment and Partnership to Advance Next-Generation Vaccine Development - Nasdaq

Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment - GlobeNewswire

Mar 12, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewswire Inc.

Mar 12, 2025

Mar 11, 2025

Rhumbline Advisers Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World

Mar 11, 2025

Syngene buys its first manufacturing facility in US for USD36.5 million - Medical Dialogues

Mar 11, 2025

Mar 10, 2025

Emergent BioSolutions Sells Baltimore Facility to Syngene - TipRanks

Mar 10, 2025

Gaithersburg's Emergent BioSolutions to sell Baltimore plant for $36.5M - The Business Journals

Mar 10, 2025

Drug manufacturer to sell Baltimore plant for $36.5M - The Business Journals

Mar 10, 2025

Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com Canada

Mar 10, 2025

Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln - TradingView

Mar 10, 2025

India's Syngene International acquires first US biologics facility for $36.5 million - Yahoo Finance

Mar 10, 2025

Emergent to Sell Baltimore-Bayview Facility for $36.5 Million -March 10, 2025 at 10:28 am EDT - Marketscreener.com

Mar 10, 2025

Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com

Mar 10, 2025

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International - The Manila Times

Mar 10, 2025

Emergent BioSolutions to sell Baltimore-Bayview facility for $36.5M - TipRanks

Mar 10, 2025

Mar 07, 2025

Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 07, 2025

Q1 Earnings Estimate for EBS Issued By HC Wainwright - Defense World

Mar 07, 2025

Mar 06, 2025

Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance

Mar 06, 2025

Mar 05, 2025

Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load? - Simply Wall St

Mar 05, 2025

Mar 04, 2025

Emergent BioSolutions’ Earnings Call: Balancing Achievements and Challenges - TipRanks

Mar 04, 2025

Emergent BioSolutions Reports Strong 2024 Financial Turnaround - MSN

Mar 04, 2025

Where Emergent BioSolutions Stands With Analysts - Benzinga

Mar 04, 2025

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 04, 2025

H.C. Wainwright maintains Buy rating on Emergent BioSolutions stock By Investing.com - Investing.com UK

Mar 04, 2025

Emergent Bio's Q4 Revenue Plunges Nearly 30%, Forecasts 18% To 28% Drop For 2025 - Nasdaq

Mar 04, 2025

Emergent BioSolutions Inc. SEC 10-K Report - TradingView

Mar 04, 2025

(EBS) Trading Signals - Stock Traders Daily

Mar 04, 2025